Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $13.82
Previous CloseN/A
Volume547.29K
Average Volume (3M)953.52K
Market Cap
$255.47M
Enterprise Value$69.54M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 18, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding44,506,527
10 Day Avg. Volume497,242
30 Day Avg. Volume953,522
Standard Deviation0.33
R-Squared0.00197
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.55
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$11.33Price Target Upside103.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Verastem News
PremiumCompany Announcements
Verastem Expands Oncology Pipeline with VS-7375 Acquisition
PremiumCompany Announcements
Verastem Appoints Matthew E. Ros as COO
PremiumCompany Announcements
Verastem Strengthens Financials and Partnerships for Drug Launch---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyThe combination of avutometinib and defactinib shows a significant improvement in efficacy over current regimens, with a relevant reduction in tumor size and better tolerability.
Financial OutlookRecent debt refinancing and new credit facilities are seen positively, as they improve VSTM's financial stability and extend its cash runway.
Bears Say
Regulatory ChallengesVSTM shares are down approximately 20% due to the news that the company will initially seek approval only in KRAS-mutant patients, not KRAS-wild-type patients.
---
Ownership Overview
1.40% Insiders
6.46% Mutual Funds
42.49% Other Institutional Investors
41.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.10 and its highest was $13.82 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $255.47M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Mar 18, 2025 which is in 25 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 06, 2024. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.738 by $0.138.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.83.
How many shares outstanding does Verastem have?
Verastem has 44,506,527 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.738. Following the earnings report the stock price went down -6.977%.
Which hedge fund is a major shareholder of Verastem?
Among the largest hedge funds holding Verastem’s share is Viking Global Investors LP. It holds Verastem’s shares valued at 0.
---
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (103.41% Upside)
$11.33 (103.41% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.61%
12-Months-Change
Fundamentals
Return on Equity
-136.87%
Trailing 12-Months
Asset Growth
-28.26%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
VSTM Stock 12 Month Forecast
Average Price Target
$11.33
▲(103.41% Upside)
Technical Analysis
Best Analysts Covering VSTM
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+4.75%
reiterated a buy rating last month
Copying Justin Zelin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.75% per trade.
---